Fulton Bank N.A. Sells 852 Shares of Edwards Lifesciences Co. (NYSE:EW)

Fulton Bank N.A. lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 13.4% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 5,511 shares of the medical research company’s stock after selling 852 shares during the period. Fulton Bank N.A.’s holdings in Edwards Lifesciences were worth $408,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of EW. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences during the third quarter valued at approximately $32,000. Avior Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the period. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences in the third quarter worth $40,000. Finally, JFS Wealth Advisors LLC raised its position in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on EW shares. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Evercore ISI dropped their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Finally, The Goldman Sachs Group lifted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Sixteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.40.

Edwards Lifesciences Stock Down 1.0 %

NYSE EW opened at $73.41 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a market capitalization of $43.30 billion, a price-to-earnings ratio of 10.59, a PEG ratio of 3.61 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $71.64 and a two-hundred day moving average of $72.19.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 EPS. On average, analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,500 shares of company stock worth $2,508,350 in the last quarter. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.